Article Text

Download PDFPDF
Leukotriene receptor antagonists - an update
  • Relevant BNF sections: 3.1, 3.3.2


Montelukast (Singulair - MSD) and zafirlukast (Accolate - AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma. In 1998, soon after their launch, we concluded that there was insufficient evidence to clearly define their place in treatment.1 Here, we reconsider their role in adults and children with asthma in the light of more recent evidence.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.